바이오트(BTMD) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

BTMD

biote Corp

7월 27일 4:00 PM ET (한국 7/28 05:00)

$2.33

+0.05 ▲ +2.19%

🌙 7월 27일 7:05 PM ET (한국 7/28 08:05)

$2.23

-0.10 ▼ -4.29%

바이오트(BTMD) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$88M

스몰캡

P/E

5.2

저평가 구간

배당수익률

없음

52주 위치

30%

저점 +83% · 고점 -51%

애널리스트

적극 매수

Fundamental health

vs. Medical Care Facilities

수익성

Top 5%

성장

Top 61%

밸류에이션

Top 93%

재무 안정

Top 78%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 3년 (not other companies).

Very cheap

Cheap

Typical

Pricey

Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 6원. Over the past 3년, it usually traded around 11원. On the cheaper side versus its own history.

Pricy doesn't mean bad — it means expectations are already baked in.· based on 3.1 profitable years

Index ⓘ	-	P/E ⓘ	5.18	EPS (ttm) ⓘ	0.45	Insider Own ⓘ	9.39%	Shs Outstand ⓘ	30.0M	Perf Week ⓘ	-6.43%
Market Cap ⓘ	0.09B	Forward P/E ⓘ	5.42	EPS next Y ⓘ	34.37%	Insider Trans ⓘ	-	Shs Float ⓘ	27.5M	Perf Month ⓘ	18.88%
Enterprise Value ⓘ	0.20B	PEG ⓘ	-	EPS next Q ⓘ	0.03	Inst Own ⓘ	66.02%	Short Float ⓘ	2.11%	Perf Quarter ⓘ	2.19%
Income ⓘ	0.02B	P/S ⓘ	0.47	EPS this Y ⓘ	-56.76%	Inst Trans ⓘ	-0.69%	Short Ratio ⓘ	2.09	Perf Half Y ⓘ	5.43%
Sales ⓘ	0.19B	P/B ⓘ	-	EPS next 5Y ⓘ	-6.24%	ROA ⓘ	14.69%	Short Interest ⓘ	0.58M	Perf YTD ⓘ	-10.38%
Book/sh ⓘ	-1.87	P/C ⓘ	16.46	EPS past 3/5Y ⓘ	- 11.37%	ROE ⓘ	-	52W High ⓘ	-50.95% ($4.75)	Perf Year ⓘ	-46.06%
Cash/sh ⓘ	0.14	P/FCF ⓘ	3.03	Sales past 3/5Y ⓘ	5.23% 10.52%	ROIC ⓘ	34.32%	52W Low ⓘ	83.46% ($1.27)	Perf 3Y ⓘ	-65.53%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	5.56	EPS Y/Y TTM ⓘ	-29.34%	Gross Margin ⓘ	68.45%	Volatility(W/M) ⓘ	6.65% 8.58%	Perf 5Y ⓘ	-76.05%
Dividend TTM ⓘ	-	EV/Sales ⓘ	1.06	Sales Y/Y TTM ⓘ	-5.63%	Oper. Margin ⓘ	16.99%	ATR (14) ⓘ	0.16	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	0.57	EPS Q/Q ⓘ	-82.95%	Profit Margin ⓘ	8.29%	RSI (14) ⓘ	53.57	Recom ⓘ	1.5
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	1.29	Sales Q/Q ⓘ	-8.28%	SMA20 ⓘ	3.95% ($2.24)	Beta ⓘ	1.62	Target Price ⓘ	$2.73
Payout ⓘ	-	Debt/Eq ⓘ	-	Earnings ⓘ	2026/8/5	SMA50 ⓘ	7.12% ($2.18)	Rel Volume ⓘ	0.74	Prev Close ⓘ	$2.28
Employees ⓘ	223	LT Debt/Eq ⓘ	-	EPS/Sales Surpr. ⓘ	26.32% -2.36%	SMA200 ⓘ	3.13% ($2.26)	Avg Volume(3M) ⓘ	0.28M	Price ⓘ	$2.33
IPO ⓘ	2021/4/28	Option/Short ⓘ	No/Yes			Trades ⓘ	1986	Volume ⓘ	203,805	Change ⓘ	2.19%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $45M (YoY -8%) · 순이익 $2M (YoY -83%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 biote Corp (BTMD) Investment Analysis

What kind of company is biote Corp?

바이오트(BTMD) 가치주

Healthcare · Medical Care Facilities

Small-Cap — Low Volume, High Volatility

💊 This is a US healthcare company that supplies hormone balance management pellet procedures and related nutritional supplements to a network of medical professionals. Founded in 2011 by Gary Donovitz, the company operates a business model that bundles products, education, and practice expansion support to enable its affiliated medical practitioners to offer pellet procedures to their patients.

Market Cap

$0.1B

Approx. KRW 0.1 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank4615

Employees223people

IPO2021/04/28

Current Price$2.33 ≈ 3,192원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release D-8

8월 5일 (수) · 장 마감 후

예상 매출 - · EPS $0.08

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 6일 (수) · 장 마감 후 EPS +26.3% 매출 -2.4%

🔔 Earnings release 2026년 3월 11일 (수) · 장 마감 후 EPS +50.0% 매출 +1.3%

Is it profitable?

Profitability healthy

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

17.0%

✓ 우수

My positionTop 5%

Low range Average High range

Medical Care Facilities Median 5.8% · Top 2%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

8.3%

✓ 우수

My positionTop 25%

Low range Average High range

Medical Care Facilities Median 2.5% · Top 24%

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

68.5%

✓ 우수

My positionTop 5%

Low range Average High range

Medical Care Facilities Median 19.2% · Top tier

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROA

Annual earnings relative to total company assets

14.7%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -59.3% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

34.3%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -77.3% · Top tier

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Current Ratio

Liquid assets available to cover liabilities due within a year

1.29

✓ 평균

My positionMid-range

Low range Average High range

Medical Care Facilities Median 1.35

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

0.57

✓ 매우 부진

My positionBottom 5%

Low range Average High range

Medical Care Facilities Median 1.19

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$2.73

현재가 대비 +17.2%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

5.42배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

내년 EPS 예상 성장률

+34.4%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

-6.2%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility

Frequently misses analyst estimates

예상 상회

예상 부합

예상 하회

상회 비율

-16.0%

평균 서프라이즈

2026.05.06

하회

실적 $0.08 · 예상 $0.08 -2.1%

2026.03.11

하회

실적 $0.07 · 예상 $0.10 -29.8%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Expected to Slow

Historical growth is expected to lose momentum

Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-56.8%

부진

My positionBottom 25%

Low range Average High range

가치주 초소형주 Median 7.1% · Bottom 21%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+34.4%

양호

My positionMid-range

Low range Average High range

가치주 초소형주 Median 16.0% · Top 35%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

-6.2%

매우 부진

My positionBottom 5%

Low range Average High range

Medical Care Facilities Median 10.6% · Bottom tier

📊 How much has it grown? (actual results)

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+11.4%

양호

My positionMid-range

Low range Average High range

가치주 초소형주 Median 9.4% · Top 47%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+10.5%

양호

My positionMid-range

Low range Average High range

가치주 초소형주 Median 7.3% · Top 32%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-8.3%

부진

My positionBottom 25%

Low range Average High range

가치주 초소형주 Median 5.3% · Bottom 24%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -144%p below the market

BTMD -76.0% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-144.4%p

Significantly behind the market

vs Health Care (XLV)

-100.5%p

Significantly behind the sector average

1-year basis

vs S&P 500

-62.1%p

Significantly behind the market

vs Health Care (XLV)

-65.8%p

Significantly behind the sector average

Rank among peers

1-year return Lower-Mid (lower 49%) Based on 10 peers

Current position within 52-week range

Low (-83.5%p) High (-51.0%p)

Current price is 83.5% above the 52-week low and 51.0% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-41.7%

Annualized volatility

74.8%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-27

Uptrend zone

Current price $2.33 above the midline ($2.24). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

⚡

Current diagnosis · 2026-07-27

Death cross — bearish reversal signal

MACD(0.055) crossed below Signal(0.055). Trend reversal possible; read as a sell entry point.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-27

Bullish zone

RSI 53.5 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 46.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Earnings·Vs. Sales·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Cheap

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

5.18x

✓ Very cheap

My positionTop 5%

Low range Average High range

Medical Care Facilities median 19.84x · Top 1% — relatively cheap within the industry

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

5.42x

✓ Very cheap

My positionTop 5%

Low range Average High range

Medical Care Facilities median 18.77x · Top 1% — relatively cheap within the industry

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

0.47x

✓ Very cheap

My positionTop 25%

Low range Average High range

Medical Care Facilities median 0.92x · Top 25% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

5.56x

✓ Very cheap

My positionTop 25%

Low range Average High range

Medical Care Facilities median 11.60x · Top 10% — relatively cheap within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

3.03x

✓ Very cheap

My positionTop 5%

Low range Average High range

Medical Care Facilities median 14.23x · Top 1% — relatively cheap within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$2.73 vs. current price +17.2%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Medical Care Facilities

Who owns it?

Ownership flow is positive

Institutional modest net selling -0.7% · Short interest light 2.1% · Short interest fell -2.8%p over the last 90 days

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

-0.7%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 66.0%

Adequate institutional weight

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 9.4%

Meaningful insider stake

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 24.6%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

2.1%

Low — limited short-side pressure

Healthcare 초소형주 Median 3.9%

Past 90 days 📉 -2.8%p decrease

Short interest days to cover

2.1 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 30.0M주

Float (tradable shares) 27.5M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding BTMD

ETFs with the highest weightings · 10 total shown

IVSS

Applied Finance IVS US SMID ETF

0.02%

$28M

IWC

iShares Micro-Cap ETF

0.01%

$1.4B

FLQS

Franklin U.S. Small Cap Multifactor Index ETF

0.00%

$51M

HDG

ProShares Hedge Replication ETF

0.00%

$22M

HONG

Leverage Shares 2X Long HON Daily ETF

0.00%

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
BTMD This Stock	$87.6M	5.2 ▲	-	-	-	+2.2%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 바이오트(BTMD)?

바이오트(BTMD) belongs to the Healthcare sector and operates in the Medical Care Facilities industry.

What is the market cap of BTMD?

The market cap of BTMD is approximately $88M, ranking 4,615 within its sector.

What is the P/E ratio of BTMD?

BTMD has a P/E ratio of approximately 5.2x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for BTMD?

BTMD has recorded a 52-week high of $4.75 and a low of $1.27.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.